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Abstract Low inﬁltration of lymphocytes into cancers is
associated with poor prognosis, but the reasons why some
patients exhibit a low and others a high inﬁltration of
tumors are unknown. Previously we mapped four loci
(Lynf1–Lynf4) controlling lymphocyte inﬁltration of mouse
lung tumors. These loci do not encode any of the molecules
that are involved in trafﬁc of lymphocytes. Here we report
a genetic relationship between these loci and the control of
production of IFNc in allogeneic mixed lymphocyte
cultures (MLC). We found that IFNc production by
lymphocytes of O20/A mice is lower than by lymphocytes
of OcB-9/Dem mice (both H2
pz) stimulated in MLC by
irradiated splenocytes of C57BL/10SnPh (H2
b) or BALB/
cHeA (H2
d) mice, or by ConA. IFNc production in MLCs
ofindividual(O20 9 OcB-9)F2micestimulatedbyirradiated
C57BL/10 splenocytes and genotyped for microsatellite
markers revealed four IFNc-controlling loci (Cypr4-Cypr7),
each of which is closely linked with one of the four Lynf loci
andwithaclusterofsusceptibilitygenesfordifferenttumors.
This suggests that inherited differences in certain lympho-
cyte responses may modify their propensity to inﬁltrate
tumors and their capacity to affect tumor growth.
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Abbreviations
Cypr Cytokine production
Lynf Lymphocyte inﬁltration
MLC Mixed lymphocyte culture
MLR Mixed lymphocyte reaction
QTL Quantitative trait locus
Introduction
Interaction between the immune system and cancer is one
of the most important determinants of cancer growth,
progression, and metastasis. The interconnected processes
of innate and adaptive immunity co-determine the devel-
opment of cancer from the very beginning, when acute
inﬂammation tends to suppress and chronic inﬂammation
to promote carcinogenesis [1]. The interaction of adaptive
immunity with cancer is less clear. It is a powerful agent
in rejection of virally induced tumors [2], but its effects
on spontaneous and carcinogen-induced tumors are still
subject of discussion [3, 4]. Recently, however, in a
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ence of inﬁltrating CD3
? T lymphocytes is a positive
prognostic factor [5], although in some studies their effect
was mitigated by presence of T regulatory lymphocytes [6].
This indicated a positive role of CD3
? T lymphocytes in
suppression of cancer. However, it is not known why
inﬁltrating T lymphocytes are abundant in cancers of some
patients but scarce in others. Although in the past decade, a
large progress has been made in unravelling the sequence
of molecular steps that participate in the passage of lym-
phocytes from blood circulation into tumor, and more than
60 different molecules (or closely related members of the
same family) that facilitate and mediate lymphocyte trafﬁc
were identiﬁed [7], differences in structure or expression of
these molecules were not yet correlated with individual
propensity to tumor inﬁltration.
To the contrary, a new insight into the regulation of
lymphocyte inﬁltration in tumors has been provided by the
observations that the presence of inﬁltrating lymphocytes
in mouse lung tumors is pronounced in some strains but
virtually absent in others [8] and that this difference is
controlled by four chromosomal loci designated Lynf1–
Lynf4 (Lynf = Lymphocyte inﬁltration) that determine the
presence of intra-tumoral inﬁltrating lymphocytes [9]i na
cross between strains O20/A and OcB-9/Dem. Surpris-
ingly, none of the four Lynf loci (Lynf1—chromosome 4;
Lynf2—chromosome 8; Lynf3 and Lynf4—chromosome 6)
encoded any of set of[60 molecules that were reported to
participate in migration of lymphocytes into tumors.
Therefore, other processes than direct molecular interac-
tions of lymphocyte and surrounding tissue may be the
primary determinants of individual’s propensity to lym-
phocyte inﬁltration of tumors.
Our previous data showed that genetic polymorphisms
of the intensity of nonspeciﬁc inﬂammation-related activity
of immunocytes are linked with cancer susceptibility
genes. We deﬁned previously two loci, Marif1 controlling
production of IL-12, TNFa and iNOS, and Marif2 con-
trolling production of TNFa and IL-12, by in vitro stimu-
lated bone marrow-derived macrophages [10], and two
loci, Cinda3 and Cinda5, controlling in vitro proliferative
response of lymphocytes to cytokines IL-2 and IL-4 [11].
Marif1 and Cinda3 are linked to each other and Cinda3 is
closely linked to Lynf1 as well as the mouse lung cancer
susceptibility loci Sluc6/Sluc21 on chromosome 4. Marif2
and Cinda5 are linked to each other and to Lynf2 as well as
to the mouse lung cancer susceptibility locus Sluc20 on
chromosome 8. This suggests a possible functional con-
nection between activation of immunocytes and capacity of
tumor inﬁltration.
In the present study, we analysed the genetic control of
production of another cytokine, IFNc, during in vitro
reaction to major histocompatibility complex (MHC) allo-
antigens. The differences in the MHC antigens induce the
strongest responses [12]. But genetic disparity in minor
alloantigens also modiﬁes the alloresponse. Earlier studies
found that some strong MLC-stimulations (Mls) antigens
are coded by mouse Mtv (mammary tumor virus) [13]; later
studies revealed a broad spectrum of additional minor
human antigens [14]. Intensity of MLC-response to allo-
antigens is determined by two major factors—the genetic
disparity between the responding and stimulating cells and
the genetically deﬁned intrinsic capacity of the responding
cells to react to the stimulus [15–17].
Responder cells react to stimulator cells by proliferation
and by cytokine production. We have studied the genetic
basisofthesetworesponses,usingtherecombinantcongenic
(RC) strains, which were developed for analysis of multi-
genically controlled biological processes [18]. A series of
RC strains is derived from two parental inbred strains: a
‘‘background’’strainanda‘‘donor’’strain.EachoftheseRC
strains contains a different subset of about 12.5% of genes
from the parental donor strain and the remaining approxi-
mately 87.5% of background strain genes. The BALB/
cHeA-c-STS/A (CcS) and O20/A-c-B10.O20/Dem (OcB)
series of strains were used previously for analysis of allo-
antigen response. The strain distribution pattern of magni-
tude of proliferative response in MLR of individual RC
strainstostimulatorcells offourdifferentstrainswas almost
identical, indicating that differences in responsiveness,
rather than the alloantigenic difference itself, determine the
magnitude of the response, and that the responsiveness to
differentMHCalloantigensislargelycontrolledbythesame
genes [19, 20]. We have mapped previously two of these
responsiveness genes, Alan1 and Alan2 (Alloantigen
response 1, 2) located on chromosomes 17 and 4, respec-
tively, that control differences in proliferative response to
severalalloantigensinCcSandOcB RCstrains[16,17].We
have also shown that in the individual RCS the levels of
proliferationandIL-2 productioninMLRarenotcorrelated,
and therefore these two responses are under a different
genetic control [19].
In the present work we deﬁned four loci, Cypr4–Cypr7
(Cypr = Cytokine production), that control IFNc production
by responder cells in MLR. IFNc plays important role in
immunity against infection, and it has been associated with a
number of autoinﬂammatory and autoimmune diseases
(reviewedin[21]).IFNchasalsomultipleanddiverseessential
functions in immune response to cancer [22–25]. For that rea-
son, genetics of capacity of IFNcproduction may be important
for a variety of biological reactions. Here we show that control
of IFNc production is genetically linked to and possibly
responsible for the control of intensity of lymphocyte inﬁltra-
tion in tumors and control of tumor growth and progression.
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Mice
Males and females of strains O20/A (abbrev. O20), OcB-9/
Dem (abbrev. OcB-9) (both strains have the MHC haplo-
type H2
pz) and F2 hybrids between O20 and OcB-9 came
from P. Demant’s breeding colony. The haplotype H2
pz is
described in [26]. The genetic composition of strain OcB-9
has been described in detail by Stassen and co-workers
[27]. When used for these experiments strain OcB-9 passed
more than 31 generations of brother–sister mating and was
highly homozygous. C57BL/10SnPh (abbrev. B10) (H2
b)
mice were from the Institute of Molecular Genetics (Pra-
gue). As the strains O20 and OcB-9 are MHC identical, all
mixed lymphocyte reactions tested in this paper involved
the same MHC incompatibility (H2
pz–H2
b).
Mixed lymphocyte culture
Spleen cells of O20, OcB-9, and of individual F2 hybrid
mice (6 9 10
5 cells per well) were mixed with 8 9 10
5
irradiated (3000 R) C57BL/10 stimulator cells in 800 lli n
24-well tissue culture plates in complete RPMI 1640
medium, respectively (Nunc, Roskilde, Denmark) [28].
Supernatants were removed after 96 h incubation period
and stored at -70C before use. Each day in a separate
experiment 20 F2 mice and appropriate controls (O20 and
OcB-9 mice) were tested. In the experiments, comparing
IFNc, IL-2, and IL-4 production by stimulated lymphocytes
of strains O20 and OcB-9, supernatants were removed also
48 and 72 h after stimulation.
Concanavalin A-stimulated cultures
Spleen cells (4 9 10
5 cells per well) were incubated in
800 ll in 24-well tissue culture plates in complete RPMI
1640 medium with 2.5 lg/ml ConA. Supernatants were
collected after 24, 48, or 72 h of incubation and assayed for
IFNc presence.
Estimation of cytokine levels
Supernatants from MLR cultures were assayed for IFNc,
IL-2, and IL-4 presence using the primary and secondary
mAbs (R46A2, XMG1.2; JES6-1A11, JES6-5H4; 11B11,
BVD6-24G2) and standards (mIFNc,m I L - 2 ,a n dm I L - 4 )
from BD Bioscience, San Jose, CA. Similarly, superna-
tants from ConA stimulated cultures were assayed for
IFNc. The ELISA was performed using the conditions
recommended by BD Bioscience. In brief, a 96-well ﬂat-
bottom plate (Costar, Cambridge, MA) was coated with
primary mAb at a concentration of 1 lg/ml in 0.1 M
NaHCO3 pH 8.2 and incubated overnight at 4C. The
plates were washed with PBS-Tween (Costar, Corning,
NY) and incubated for 2 h with 200 ll of PBS 8% BSA.
After washing, aliquots of supernatants were added to
duplicate wells and incubated overnight at 4C. Plates
were washed again and biotin-labeled secondary mAb
was added for 45 min. Plates were washed, followed by
addition of horseradish peroxidase streptavidin (Vector
Laboratories, Burlingame, CA). 2,20-azino-bis(3-ethyl-
benzthiazoline-6-sulfonic acid) (Sigma-Aldrich, St. Louis,
MO) and peroxide were used as chromogen. Color reac-
tion was stopped by sodium dodecyl sulfate (SDS) in N,N-
dimethylformamide and plates were read at OD 405 nm
and the IFNc levels were estimated by the ELISA reader
Tecan and the curve ﬁtter program KIM-E (Schoeller
Pharma, Prague, Czech Republic) using least square
nonlinear regression analysis. Sensitivity of detection of
IFNc, IL-2, and IL-4 levels in supernatants was 32, 4, and
15 pg/ml, respectively.
Genotyping of microsatellites by PCR
DNA was isolated from tails using a standard proteinase
procedure. The strain OcB-9 differs from O20 by carrying
B10.O20-derived segments at 10 chromosomes [27]. These
differential segments were typedin the F2hybrid mice using
15 microsatellite markers: D2Mit7, D2Mit56; D4Mit54;
D6Mit31, D6Mit52; D7Mit12, D7Nds2; D8Mit3, D8Mit65;
D10Mit12; D11Mit15; D16Mit130; D18Mit17; D19Mit3,
D19Mit63. These markers were selected because they cover
optimally the chromosomal segments at which the OcB-9
strain has genetic material from the B10.O20 strain. They
carry different alleles in the two parental strains, the O20
allele (designated o), and the B10.O20 allele (designated b).
PCR genotyping was performed as described [29]. Brieﬂy,
ampliﬁcation was performed with a MJ Research Thermal
Cycler PTC 100 Model 96 (MJ Research, Watertown, MA)
in a volume of 10 ll with 20 ng DNA, 0.23 lM of forward
primer [c-
32P]ATP end-labeled with T4 polynucleotide
kinase (New England Biolabs, Schwalbach, Germany),
0.23 lMofreverseprimer,200 lMofeachdNTPand0.04u
Taqpolymerase(GIBCO,GrandIsland,NY)ina96-wellU-
bottommicrotiterplate(FALCON,Oxford,UK)with1cycle
of3 minat94Cand30cyclesof30 sat94C,1 minat55C
and 1 min at 72C and 1 cycle of 1 min at 55C, 3 min at
72C,and1 minat23C.EachPCRproductwasmixedwith
30 ll of loading buffer and electrophoresed in 6% acryl-
amide gels for 2–2.5 hat50 W. Gels were wrapped inSaran
Wrap (Dow Chemicals Co., Midland, MI) and exposed to
X-ray ﬁlm X-OMAT AR (Kodak, Weesp, The Netherlands)
for 1.5–24 h at -70C.
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The role of genetic factors in IFNc production in MLR
response was examined by analysis of variance
[ANOVA, PROC GLM statement of the SAS 8.2 for
Windows (SAS Institute, Cary, NC)]. The effect of each
marker, sex, and experiment on IFNc level in superna-
tants was tested. Each individual marker and its inter-
actions with other markers and sex or experiment were
subjected to ANOVA. A backward elimination procedure
[30] was followed wherein the interaction of marker (or
interaction) bearing the highest P value (if P[0.05)
was eliminated ﬁrst. The markers and interactions with P
value smaller than 0.05 were pooled for the next round
of ANOVA. The backward elimination procedure was
repeated till the ﬁnal set of signiﬁcant markers and
interactions was obtained. The P values (Pc = aT) were
corrected according to Lander and Kruglyak [31] using
the formula:
aT   C þ 2qGhðTÞ ½  aT
with G = 2 M (the length of the segregating part of the
genome: 12.5% of 16 M); C = 10 (number of chromo-
somes segregating in this cross); q = 1.5 for F2 hybrids;
and h(T) = the observed statistics (F ratio).
IFNc, IL-2, and IL-4 production in MLR by cells of
responder strains O20 and OcB-9 was compared by Mann–
Whitney U test (STATISTICA for Windows 5.0, StatSoft,
Inc., Tulsa, OK).
Results
Strain differences in proliferation and production
of cytokines after stimulation with alloantigen or ConA
The proliferation of lymphocytes of the strain OcB-9 in
MLC is higher than that of the MHC-identical strain
O20 (both H2
pz) after stimulation with lymphocytes of
strains with C57BL/10 (H2
b), BALB/cHeA (H2
d), and
CBA (H2
k) that carry unrelated MHC haplotypes (Fig. 1
and Ref. 17). This indicates that strain OcB-9 has a
higher propensity to respond to a variety of alloantigens
than O20. The production of IFNc in MLC is also sig-
niﬁcantly higher by OcB-9 than by O20 responder cells
when stimulated by C57BL/10 (H2
b) cells (Fig. 2a) and
BALB/c (H2
d) cells, but it is low in both with weaker
stimulators DBA (H2
q) and CBA (H2
k) (Fig. 2b). OcB-9
lymphocytes are also better producers of IFNc than O20
lymphocytes after stimulation with ConA (Fig. 3). In
MLC with C57BL/10 stimulator cells, the production of
IL-2 (Fig. 4a) but not of IL-4 (Fig. 4b) is higher by
OcB-9 than O20 responder cells.
Detection of loci that control IFNc level in MLC
Supernatants of the spleen cells of the strain OcB-9 contain
higher concentration of IFNc 96 h after stimulation with
C57BL/10 cells than supernatants of spleen cells of strain
O20 (P\0.014) (Fig. 2a). We examined production of
IFNc in 240 F2 hybrids between the strains O20 and OcB-9.
The strains O20 and OcB-9 differ in their genetic material
at 10 chromosomes [27]. These differential segments were
typed in the F2 hybrids mice using 15 microsatellite
markers listed above.
Statistical analysis revealed four genetic loci that inﬂu-
ence level of IFNc in supernatants of (O20xOcB-9)F2
splenocytes stimulated by irradiated C57BL/10 cells. Two
of these loci have individual effects, but the other two
operate in mutual nonadditive interaction. Two loci, Cypr4
(Cytokine production 4) linked to D6Mit31 (corrected P
value\0.00717) and Cypr5 linked to D6Mit52 (corrected
P value\0.000257) have effect on IFNc production after
alloantigen stimulation that is not inﬂuenced by interaction
with other genes (main effects) (Table 1). These loci have
an opposite effect on the studied trait. The homozygosity
for the O20 allele of Cypr4 (oo) determines about twofold
higher level of IFNc than the homozygosity of the B10.O20
allele (bb), whereas homozygosity for the O20 allele of
0
1000
2000
3000
4000
5000
- C57BL/10 BALB/c CBA 
Mean of proliferative response after alloantigen stimulation  
[
3
H
]
 
-
 
T
h
y
m
i
d
i
n
e
 
i
n
c
o
r
p
o
r
a
t
i
o
n
 
i
n
 
c
p
m
  O20  
OcB-9  
B10.O20 
stimulator cells 
Fig. 1 The MLC reactivity of O20, B10.O20, and OcB-9 strains.
Proliferative response of spleen cells in RPMI medium only and
stimulated by C57BL/10Sn (H2
b) (B10), BALB/c (H2
d), and CBA/Ph
(H2
k) alloantigens. Spleen cells (1.5 9 10
5 cells per well) were mixed
with 2 9 10
5 irradiated (3000 R) B10, BALB/c or CBA/Ph stimulator
cells in 200 ll in 96-well tissue culture plates. [3H]-thymidine
(0.5 lCi/well) was added into the cultures for the last 6 h of the 96-h
incubation period as described previously [17]. The data show the
mean ± SE from three independent experiments. Reproduced with
the kind permission from Ref. [17]
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123Cypr5 is associated with about two-and-half fold decrease
level of this cytokine than the homozygosity of the
B10.O20 allele. Inﬂuence of the experimental group was
evident (P\1.75 9 10
-24), but no signiﬁcant interaction
between experimental group and marker was observed.
Cypr6 inﬂuences IFNc level in interaction with Cypr7
(corrected P\0.00111). F2 mice with homozygous
B10.O20 (bb) alleles at Cypr6 and O20 (oo) alleles at
Cypr7 or homozygous for B10.O20 allele at Cypr7 and
homozygous for O20 alleles in Cypr6 produce approxi-
mately twice higher IFNc level in supernatants in alloan-
tigen-stimulated spleen cells in comparison with other
combinations of Cypr6 and Cypr7 O20 and B10.O20
alleles (Table 2). The levels of IFNc seem to be negatively
correlated with the intensity of lymphocyte inﬁltration,
both in the strains and in comparable genotypes. The
production of IFNc is higher in the strain OcB-9 than O20,
while in O20 mice the numbers of intratumoral lympho-
cytes are higher than in OcB-9 [8]. A similar negative
correlation is seen also at locus level: IFNc levels at the
three Cypr4 genotypes are negatively correlated with
lymphocyte inﬁltration scores at the corresponding
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Fig. 2 a Comparison of concentration of IFNc in supernatants of the
spleen cells of the strains OcB-9 and O20 after alloantigen
stimulation. Spleen cells (6 9 10
5 cells per well) were mixed with
8 9 10
5 irradiated (3000 R) C57BL/10 stimulator cells in 800 lli n
24-well tissue culture plates. Cell supernatants were analyzed 48, 72,
and 96 h after stimulation. Data summarize the result of 13
independent experiments. Both female and male mice were used in
our analysis, but no inﬂuence of sex on strain difference was
observed. The columns show the means ± SE of IFNc concentration
in ng/ml. Filled square: OcB-9, unﬁlled square: O20. b Comparison
of concentration of IFNc in supernatants of the spleen cells of the
strains OcB-9 and O20 after stimulation by C57BL/10Sn (H2
b),
BALB/c (H2
d), CBA (H2
k), and DBA/1 (H2
q) alloantigens. Spleen
cells (6 9 10
5 cells per well) were mixed with 8 9 10
5 irradiated
(3000 R) C57BL/10Sn, BALB/c, CBA, or DBA/1 stimulator cells in
800 ll in 24-well tissue culture plates. Cell supernatants were
analysed 72 and 96 h after stimulation. Data summarize the result of
13 independent experiments
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Fig. 3 Comparison of concentration of IFNc in supernatants of the
spleen cells of the strains OcB-9 and O20 after stimulation with
2.5 lg/ml ConA. To test IFNc concentration, 800 ll of spleen cells
(4 9 10
5 cells per well) were incubated in 24-well tissue culture
plates in complete RPMI 1640 medium with 2.5 lg/ml ConA. After
24, 48, or 72 h of incubation supernatants were collected and assayed
for IFNc presence. The columns show the means ± SE of IFNc
concentration in ng/ml. Data summarize the result of four independent
experiments. Square: OcB-9, unﬁlled square: O20
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123genotypes [9] of the co-localizing Lynf4 locus: oo: IFNc—
7.74 ng/ml, inﬁltration score (IS)—0.04; ob: IFNc—
5.77 ng/ml, (IS)—0.39; bb: IFNc—3.78 ng/ml, (IS)—0.34.
Allelic correlations within the other Cypr-Lynf could not be
assessed, because these loci were deﬁned by inter-locus
interactions.
Discussion
In the present study, we demonstrate genetic linkage
between in vitro production of IFNc and in vivo lympho-
cyte inﬁltration of tumors. Previously, we have shown that
responder’s genotype strongly inﬂuences various in vitro
responses of lymphocytes to stimulation by allogeneic cells
[16, 17], anti-CD3 antibodies [28], mitogens [32], and
cytokines [11, 28]. Importantly, in MLC these differences
in response were obvious in spite of identical MHC
incompatibility. We have shown that these differences are
controlled by several loci with quantitative additive effects,
and that different components of a response, for example
proliferation or production of different cytokines, are
controlled by different genes. We observed that two genetic
loci that control activation of macrophages [10] and lym-
phocytes [11] co-localize with the genes that control sus-
ceptibility to lung tumors. This suggested that the loci
regulating activity of lymphocytes and macrophages in
vitro could have also in vivo effect on tumor growth. The
genetic analysis of production of IFNc by responder lym-
phocytes in allogeneic mixed lymphocyte cultures dem-
onstrated four genetic loci with signiﬁcant inﬂuence. We
analyzed the difference in the phenotype of interferon
production between the strain O20 and the RC strain OcB-
9 that is in about 87.5% genes identical to O20, but
received a random subset of about 12.5% of genes from the
strain B10.O20 [18, 27]. The genetic material obtained
from B10.O20 is almost entirely contained in several
contiguous chromosomal segments, mostly 10–20 cM
long. They were described previously [27, 33] and are
covered by 15 polymorphic microsatellite markers listed in
‘‘Materials and methods’’ section. Thus, any genetic dif-
ferences between these two strains must be controlled by a
gene or genes located in one of these B10.O20-derived
segments [34]. It should be pointed out that the strains O20
and OcB-9 have identical MHC haplotype (H2
pz), so they
respond to the same MHC incompatibility (H2
b) and any
difference in the response must be host-related. The stim-
ulation by non-MHC alloantigens is not a likely cause of
the observed differences in production of IFNc between
O20 and OcB-9, because the two strains have the same
genotype at the strong stimulatory locus Mtv13 (Mls1)[ 27]
and no other stimulators in MLC were described in the
vicinity of the Cypr loci mapped here.
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Fig. 4 a Comparison of concentration of IL-2 in supernatants of the
spleen cells of the strains OcB-9 and O20 after alloantigen
stimulation. Spleen cells (6 9 10
5 cells per well) were mixed with
8 9 10
5 irradiated (3000 R) C57BL/10 stimulator cells in 800 lli n
24-well tissue culture plates. Cell supernatants were analysed 48, 72,
and 96 h after stimulation. Data summarize the result of 13
independent experiments. Both female and male mice were used in
our analysis, but no inﬂuence of sex on strain difference was
observed. The columns show the means ± SE of IL-2 concentration
in ng/ml. Filled square: OcB-9, unﬁlled square: O20. b Comparison
of concentration of IL-4 in supernatants of the spleen cells of the
strains OcB-9 and O20 after alloantigen stimulation. Spleen cells
(6 9 10
5 cells per well) were mixed with 8 9 10
5 irradiated (3000 R)
C57BL/10 stimulator cells in 800 ll in 24-well tissue culture plates.
Cell supernatants were analysed 48, 72, and 96 h after stimulation.
Data summarize the result of 13 independent experiments. Both
female and male mice were used in our analysis, but no inﬂuence
of sex on strain difference was observed. The columns show the
means ± SE of IL-4 concentration in ng/ml. Filled square: OcB-9,
unﬁlled square: O20
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123However, the higher production of IFNc by OcB-9 cells
is not likely a mere consequence of a higher proliferative
response. We measured proliferation in parallel MLCs of
individual F2 hybrid animals that were tested for IFNc
production. We found in that population only one locus
controlling the proliferation, Alan2 [17]. It is linked to a
marker that is different from but relatively close (6 cM) to
the marker identifying Cypr6, so the identity of the two loci
is neither indicated nor ruled out. The other three loci
(Cypr4, 5, and 7) were not linked to proliferative activity in
MLR. This prevailing genetic independence of prolifera-
tion and IFNc production in MLC is similar to the exten-
sively documented distinct genetic control of lymphocyte
proliferation and IL-2 production in MLC [19].
An unexpected feature of our data is the complete co-
localization of the four newly detected loci Cypr control-
ling production of IFNc in mixed lymphocyte culture with
the four Lynf loci that control inﬁltration of lymphocytes
into tumors: Cypr4–Lynf4; Cypr5–Lynf3; Cypr6–Lynf1;
Cypr7–Lynf2. This general Cypr-Lynf co-localization con-
trasts sharply with a complete lack of co-localization of
Lynf loci with any genes encoding the more than 60 mol-
ecules that were either reported to participate in trafﬁc of
lymphocytes from the circulation to tumors or belong to the
same family [9]. This suggests that, contrary to the pre-
vailing emphasis in the literature, the principal control of
capacity of lymphocytes to inﬁltrate tumors might reside in
the regulation of the processes of lymphocyte activation.
In addition, the four Cypr loci described here co-localize
with or are linked to a number of loci that control suscepti-
bility to or patterns of progression of a variety of tumors that
were independentlydescribedbydifferentgroups (Table 3).
Cypr4 is linked to four such loci, Mmom1, Ots1, Pas1c,
Skts11, Cypr5 to one locus, Ltsd8, Cypr6 to 15 loci (10 of
them within 5 cM) Gct1, Ltsd4, Naad5, Nbl1, Pcts, Sluc6,
Sluc21, Ssic1, Stmn1, Tlsr3, and Cypr7 to 7 loci Dlc1, Ltq,
Ltsd3, Mfhas1, Sluc20, Scc8, Poats1.
IFNc has an important role in host defenses, in both
innate and acquired immunity. IFNc is produced by many
different cell types, such as by T cells, NK cells, NKT cells
[35] upon their stimulation by antigens or mitogens.
Macrophages and other accessory cells, such as dendritic
cells, besides having a boosting effect on IFNc production
by resting T cells [36] can themselves also produce large
amounts of IFNc [37]. The interaction of T cells with
antigen-presenting cells results in the production of IL-1,
which then activates the T cells to produce IL-2, which
promotes the IFNc production [38]. All IFNc inducers
activate T cells either in a polyclonal (mitogen or anti-
bodies) or a clonally restricted (antigen-speciﬁc) manner.
IFNc (class II interferon) mediates broad immune
responses to pathogens. It binds to IFNGR1/IFNGR2
Table 1 Effects of genotype at the loci Cypr4 and Cypr5 on the concentration of IFNc in supernatants of spleen cells of individual F2 hybrids
between OcB-9 and O20 stimulated by irradiated B10 splenocytes
Marker/locus Genotype P value Corrected P
oo ob bb
D6Mit31 (Cypr4) 7.74 ± 0.60 (n = 64) 5.77 ± 0.47 (n = 105) 3.78 ± 0.69 (n = 63) 0.000100 0.00717
D6Mit52 (Cypr5) 3.66 ± 0.74 (n = 55) 5.09 ± 0.47 (n = 121) 9.43 ± 0.66 (n = 63) 0.00000296 0.000257
The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFNc and (in brackets) the
number of mice (for computations the measured values of IFNc in supernatants (ng/ml) were normalized by natural logarithm of (value ? 0.5) to
the power of 0.005)
Table 2 Effects of genotype at the loci Cypr6 and Cypr7 on the concentration of IFNc in supernatants of spleen cells of F2 hybrids between
OcB-9 and O20 stimulated by irradiated B10 splenocytes
D8Mit3 (Cypr7)
oo ob bb
D4Mit54 (Cypr6)
oo 5.57 ± 1.89 (n = 15) 3.13 ± 0.93 (n = 29) 10.64 ± 1.57 (n = 10)
ob 5.16 ± 0.83 (n = 31) 5.66 ± 0.55 (n = 58) 4.67 ± 0.69 (n = 33)
bb 9.06 ± 1.38 (n = 10) 4.77 ± 0.77 (n = 28) 4.61 ± 0.85 (n = 11)
The phenotypic values given for individual genotypes indicate mean and standard errors of the concentration of IFNc and (in brackets) the
number of mice. (B10.O20 allele b, O20 allele o), P value = nominal P value, corrected P = P value corrected for total genome screen)
P value = 0.000189, corrected P value = 0.00111
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123receptor complex and uses JAK1/JAK2/STAT1 signaling
pathway (reviewed in [39]). IFNc modulates the expression
of major histocompatibility antigens on many different
accessory cells, and thus stimulates interaction of these
cells with T cells. Enhanced expression of class II antigens
after IFNc treatment also takes place on cells of T and B
lineage [40]. In the nonlymphoid organs, increased MHC
antigens are found mainly on capillary endothelial cells, on
renal tubular cells and on bronchiolar epithelial cells.
The role IFNc in suppression of tumor growth has been
known for long time and the extensive literature cannot be
reviewed here. Availability of genetically modiﬁed mice
allowed to demonstrate also the role of IFNc in various
aspects of anti-tumor immune responses [22–24, 41]. In
some tests, it has been shown that this role may differ in
different mouse strains [22]. The present data show not
only a linkage between the four Cypr loci that control
production of IFNc, but also an apparently negative cor-
relation between the IFNc levels and intensity of inﬁltra-
tion, not only in the tested strains, but also when comparing
different alleles. However, the statistical signiﬁcance of
this relationship is not clear. Moreover, we are comparing
results of a short-term assay (production of IFNc in MLR)
and a condition of long duration (intensity of lymphocyte
Table 3 Co-localization of the four Cypr loci with cancer susceptibility loci/genes
Locus with
border markers
Marker cM Locus/Gene cM Reference
O20 (o) D6Mit29 36.50 Lynf4 (Lymphocyte inﬁltration 4) 35.15 [9]
B10 (b) D6Mit31 38.50 Skts11 (skin tumor susceptibility 11) 36.50 [42]
Cypr4 (b) D6Mit31 38.50 Pas1c (pulmonary adenoma susceptibility 1c) 37.00 [43]
B10 (b) D6Mit327 46.50 Mmom3 (mammary modiﬁer of Min3) 38.50 [44]
O20 (o) D6Mit10 48.70 Ots1 (ovarian teratoma susceptibility 1) 40.00 [45]
O20 (o) D6Mit334 60.75 Ltsd8 (lung tumor shape-determining 8) 61.20 [46]
B10 (b) D6Mit256 60.95 Lynf3 (Lymphocyte inﬁltration 3) 61.20 [9]
Cypr5 (b) D6Mit52 61.40
B10 (b) D6Mit370 62.67
O20 (o) D6Mit13 63.60
O20 (o) D4Mit37 56.50 Lci (liver cell immortalization) 57.50 [47]
B10 (b) D4Mit11 57.40 Naad4 (Neu associated allelic deletion 4) 57.40 [48]
Cypr6 (b) D4Mit54 66.00
Ril3 (radiation-induced leukemia sensitivity 3) 60.00 [49]
Sluc21 (susceptibility to lung cancer 21) 63.00 [30]
Tlsr3 (thymic lymphoma suppressor region 3) 63.10 [50]
Stmn1 (stathmin 1) 65.70 [51]
Naad5 (Neu associated allelic deletion 5) 66.00 [52]
Ltsd4 (lung tumor shape-determining 4) 67.00 [46]
Sluc6 (susceptibility to lung cancer 6) 67.00 [53]
Lynf1 (Lymphocyte inﬁltration 1) 67.00 [9]
Ssic1 (susceptibility to small intestinal cancer 1) 67.00 [54]
Nbl1 (neuroblastoma, suppression of tumorigenicity 1) 70.00 [55]
Pcts (plasmacytoma susceptibility) 70.00 [56]
Gct1 (granulosa cell tumorigenesis 1) 71.00 [57]
B10 (b) D4Mit342 77.50 Pctr2 (plasmacytoma resistance 2) 73.50 [58]
O20 (o) D4Mit59 78.90 Tlsr2 (thymic lymphoma suppressor region 2) 76.60 [50]
O20 (o) Markers start at 1 cM Scc8 (colon tumor susceptibility 8) 4.0 [59]
Poats1 (post-ovarectomy adrenal tumor susceptibility 1) 8.0 [60]
Ltsd3 (lung tumor shape-determining 3) 10.00 [46]
B10 (b) D8Mit155 1.00 Sluc20 (susceptibility to lung cancer 20) 10.00 [30]
Cypr7 (b) D8Mit3 10.00 Lynf2 (lymphocyte inﬁltration 2) 10.00 [9]
Mfhas1 (malignant ﬁbrous histiocytoma ampliﬁed sequence 1) 20.00 [61]
B10 (b) D8Mit98 28.00 Dlc1 (deleted in liver cancer 1) 21.00 [62]
O20 (o) D8Mit66 28.00 Ltq (lung tumor QTL) 30.00 [63]
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123inﬁltration in tumors). Before the responsible Cypr-Lynf
genes are identiﬁed, it is difﬁcult to assess, which of the
multiple effects of IFNc on lymphocytes, other inﬂamma-
tory cells, vasculature, and tumor cells modiﬁes the level of
inﬁltration. Cypr-Lynf congenic strains, currently under
production, will create possibilities for more detailed
studies of function of these genes.
The data presented here may be a suitable model for
analysis of the potent modifying effects of inﬁltrating
lymphocytes in human cancer. Although the mechanisms
of the suppressive effects of lymphocyte inﬁltration on
growth of human cancers are not known, it is interesting
that there is an extensive genetic association between the
four Cypr-Lynf loci and more than 20 loci controlling
susceptibility to and progression of a variety of mouse
tumors (Table 3). Each of the four Cypr/Lynf loci is linked
to a number of susceptibility loci to various tumors
including lung, skin, ovary, liver, mammary gland, lympho-
mas, leukemia, plasmacytoma, and histiocytoma. This multi-
plicityoftumortypesaffectedbytheseloci/genesiscompatible
with a genetic effect that is not organ speciﬁc but possibly
systemic, like control of effective immunosurveillance.
In conclusion, our data provide a novel link between
genetic polymorphisms of regulation of lymphocyte acti-
vation and genetic variation in immunoregulation of tumor
growth. Analysis of the genes involved and their human
homologues may contribute to the understanding of indi-
vidual predisposition to a high or low anti-tumor activity of
lymphocytes and thus improve the decisions about per-
sonalized selection of appropriate therapies.
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